Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
出版年份 2017 全文链接
标题
Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
作者
关键词
-
出版物
Frontiers in Oncology
Volume 7, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2017-05-09
DOI
10.3389/fonc.2017.00072
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- 996PCETUXIMAB RELATIVE DOSE INTENSITY (RDI) IN RECURRENT/METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN): FIRST OBSERVATIONAL PROSPECTIVE STUDY IN UNSELECTED PATIENTS (DIRECT TRIAL)
- (2017) J. Guigay et al. ANNALS OF ONCOLOGY
- A comparative study of PD-L1 diagnostic assays in squamous cell carcinoma of the head and neck (SCCHN)
- (2016) M.J. Ratcliffe et al. ANNALS OF ONCOLOGY
- Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141
- (2016) Maura L. Gillison et al. CANCER RESEARCH
- Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients
- (2016) S. Trivedi et al. CLINICAL CANCER RESEARCH
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
- (2016) Laura Q.M. Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response inKRASwild-type metastatic colorectal cancer patients
- (2016) Cristiana Lo Nigro World Journal of Gastrointestinal Oncology
- Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer
- (2016) John Pradeep Veluchamy et al. PLoS One
- Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study
- (2015) J. Guigay et al. ANNALS OF ONCOLOGY
- Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
- (2015) L. Apetoh et al. ANNALS OF ONCOLOGY
- Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma
- (2015) Vandana Singh Kushwaha et al. CANCER BIOLOGY & THERAPY
- DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis
- (2015) Jonathan F. Goodwin et al. CANCER CELL
- Abstract 1327: Variable impact of chemotherapy +/- cetuximab on immune modulation in a prospective cohort of 163 cancer patients:
- (2015) Cristiana Lo Nigro et al. CANCER RESEARCH
- 2865 Outcome of systemic treatments after first line platinum and cetuximab treatment in patients with recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC): A retrospective analysis
- (2015) M. Siano et al. EUROPEAN JOURNAL OF CANCER
- The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors
- (2015) Zev A Wainberg et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
- (2015) Danny Rischin et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Immunotherapy for Head and Neck Squamous Cell Carcinoma
- (2015) David W. Schoppy et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1
- (2015) Amer Assal et al. Immunotherapy
- EGFR inhibition for recurrent or metastatic HNSCC
- (2015) Athanassios Argiris LANCET ONCOLOGY
- Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
- (2015) Jean-Pascal H Machiels et al. LANCET ONCOLOGY
- Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck
- (2015) Daniel R. Simpson et al. ORAL ONCOLOGY
- PD-036: Association of HPV/p16 status with efficacy and safety in pts with OPC in the phase 3 RT/cetuximab registration trial
- (2015) J.A. Bonner et al. RADIOTHERAPY AND ONCOLOGY
- The Ipilimumab Lesson in Melanoma: Achieving Long-Term Survival
- (2015) Julie Delyon et al. SEMINARS IN ONCOLOGY
- Immune Checkpoint Protein Inhibition for Cancer: Preclinical Justification for CTLA-4 and PD-1 Blockade and New Combinations
- (2015) Kathryn Baksh et al. SEMINARS IN ONCOLOGY
- Ex Vivo Antibody-Dependent Cellular Cytotoxicity Inducibility Predicts Efficacy of Cetuximab
- (2015) Rodney J. Taylor et al. Cancer Immunology Research
- A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer
- (2015) Walter Urba et al. Journal for ImmunoTherapy of Cancer
- A Phase I, open-label, dose escalation study of MGA271 in combination with pembrolizumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck, or squamous cell non-small cell lung cancer
- (2015) Jan Baughman et al. Journal for ImmunoTherapy of Cancer
- Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle
- (2015) Robert L Ferris et al. Journal for ImmunoTherapy of Cancer
- A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck†
- (2014) T. Y. Seiwert et al. ANNALS OF ONCOLOGY
- An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
- (2014) Vassiliki Saloura et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck
- (2014) Dan P. Zandberg et al. ORAL ONCOLOGY
- Cetuximab Plus Platinum-Based Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Retrospective Study in a Single Comprehensive European Cancer Institution
- (2014) Ramon Andrade de Mello et al. PLoS One
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Optimal Management of Metastatic Renal Cell Carcinoma: Current Status
- (2013) Bernard Escudier et al. DRUGS
- Outcome of patients treated with palliative weekly Paclitaxel plus Cetuximab in recurrent head and neck cancer after failure of platinum-based therapy
- (2013) Aaron E. Sosa et al. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
- Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial
- (2013) Athanassios Argiris et al. JOURNAL OF CLINICAL ONCOLOGY
- Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
- (2013) Jan B Vermorken et al. LANCET ONCOLOGY
- Phase II Study of Cetuximab in Combination with Docetaxel in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck after Platinum-Containing Therapy: A Multicenter Study of the Arbeitsgemeinschaft Internistische Onkologie
- (2013) M. Knoedler et al. ONCOLOGY
- Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: Review of the literature and proposal for management changes
- (2013) Frédéric Peyrade et al. ORAL ONCOLOGY
- Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma
- (2012) Julien Péron et al. ANTI-CANCER DRUGS
- Current Treatment Options for Metastatic Head and Neck Cancer
- (2012) Katharine A. R. Price et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer
- (2012) Paolo Bossi et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)
- (2012) Mark Agulnik MEDICAL ONCOLOGY
- Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients
- (2012) Begoña Jiménez et al. ORAL ONCOLOGY
- Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
- (2011) R. Hitt et al. ANNALS OF ONCOLOGY
- Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
- (2011) Jean-Pascal Machiels et al. LANCET ONCOLOGY
- Optimal treatment for recurrent/metastatic head and neck cancer
- (2010) J. B. Vermorken et al. ANNALS OF ONCOLOGY
- Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) V. Gregoire et al. ANNALS OF ONCOLOGY
- MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer
- (2010) Xiaofan Zhang et al. CARCINOGENESIS
- Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape
- (2010) Robert L. Ferris et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer
- (2010) Athanassios Argiris et al. JOURNAL OF CLINICAL ONCOLOGY
- Docetaxel and irinotecan in recurrent or metastatic head and neck cancer
- (2009) Athanassios Argiris et al. CANCER
- Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck
- (2009) Byoung Chul Cho et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial
- (2009) Fernando Rivera et al. Expert Review of Anticancer Therapy
- Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies
- (2008) Jan. B. Vermorken et al. CANCER
- Head and neck cancer
- (2008) Athanassios Argiris et al. LANCET
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started